论文部分内容阅读
到达肿瘤的药物量在肿瘤化疗中特别重要。化疗一直是基于给药量和肿瘤反应之间存在关系(剂量-反应关系)的假设,该假设认为,到达肿瘤的药物量与给药量成正比。但关于药物到达人体肿瘤的定量性资料几乎没有。SPECT所提供的定量测定资料可能会明显地改变用药安排。标记药物投入后人体各器官中放射性的时间-。浓度关系资料也很有限。现已能计算SPECT测量的标记药物累积浓度,故可将医学内照射剂量(MIRD)委员会的计算结果直接用于人体。本文将介绍用定
The amount of drug that reaches the tumor is of particular importance in cancer chemotherapy. Chemotherapy has been based on the assumption that there is a relationship between dose and tumor response (dose-response relationship), which assumes that the amount of drug that reaches the tumor is proportional to the dose. However, there is almost no quantitative information on the arrival of drugs in human tumors. Quantitative data provided by SPECT may significantly alter the dosing schedule. Mark the time the radioactivity enters the human body after the drug has been administered. Concentration data is also very limited. Since the cumulative concentration of labeled drugs measured by SPECT has now been calculated, the results of the Medical Interventional Radiation Dose (MIRD) Committee can be directly applied to the human body. This article will introduce the use of fixed